Therapy Architects has a novel lead candidate with the potential to pursue FDA Fast Track approval for improved outcomes and reduction in serious side effects for leukemia. The drug is useful for treating the life threatening drug resistant mutation in chronic myeloid leukemia (CML). Therapy Architects’ drug will evolve as a front-line therapy for the treatment of CML and possibly other types of leukemia.